About

ALUNBRIG® Available From Onco360

June 1, 2021

ALUNBRIG® Available From Onco360

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

Louisville, Ky. Onco360®, the nation’s largest independent Oncology Pharmacy, has been selected by Takeda to be a specialty pharmacy partner for ALUNBRIG® (brigatinib), an oral therapy option for the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC).

Onco360 is excited to become a specialty pharmacy provider for ALUNBRIG® patients,” said Benito Fernandez, Chief Commercial Officer, Onco360. “As a provider of this important treatment option for patients, Onco360 is committed to supporting the highly specialized needs of ALK-positive metastatic NSCLC patients and their physicians across the United States.

According to the National Cancer Institute‘s (NCI) Surveillance, Epidemiology, and End Results (SEER) Program, approximately 235,760 patients will be diagnosed with lung cancer in 2021 with a corresponding 131,880 deaths. Approximately 85% of lung cancer cases are represented by NSCLC. When considering all subtypes of lung cancer, as well as stages of the disease, lung cancer patients, have a poor five-year overall survival (OS) of 21.7%. Unfortunately, 56% of lung cancer patients will have incurable, metastatic disease at the time of initial diagnosis.1 Approximately 4-to-5% of NSCLC patients have genetic mutations which can be classified as ALK-positive.2

ALUNBRIG® is manufactured by Takeda, a commercial-stage biotechnology company. The FDA’s approval of ALUNBRIG® is based upon the results of multiple clinical trials including the Phase III ALTA 1L (NCT02737501) clinical trial which demonstrated that ALUNBRIG® administration resulted in a 51% improvement in progression-free survival (PFS) compared to XALKORI in treatment-naïve patients with ALK-positive metastatic NSCLC patients.3 For full prescribing information, visit ALUNBRIG.com.

 

References:

  1. National Cancer Institute Surveillance, Epidemiology, and End Results Program. Available at Lung and Bronchus Cancer — Cancer Stat Facts . Accessed May 2021.
  2. Chia PL Mitchell P, Dobrovic A, et al. Clin Epidemiol 2014 Nov 20:6:423-32
  3. Alunbrig Prescribing Information. Available at pdf (alunbrig.com) . Accessed May 2021.

 

Media Contact:
Benito Fernandez, Chief Commercial Officer
benito.fernandez@onco360.com
516-640-1332

 

Download Press Release